- 英文名称
- Zosuquidar Trihydrochloride
- 分子式
- C32H34Cl3F2N3O2
- 分子量
- 636.99
- 中文别名
- 唑喹达盐酸盐; (2R)-1-{4-[(1AR,6R,10BS)-1,1-二氟-1,1A,6,10B-四氢二苯并[A,E]环丙并[C]环庚烯-6-基]哌嗪-1-基}-3-(喹啉-5-基氧基)丙-2-醇三盐酸盐; (R)-1-(4-((1aR,6r,10bS)-1,1-二氟-1,1a,6,10b-四氢二苯并[a,e]环丙烷[c][7]轮烯-6-基)哌嗪-1-基)-3-(喹啉-5-基氧基)丙-2-醇三盐酸盐; (R)-4-[(1aR,6R,10bS)-1,2-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cycloheptan-6-yl]-α-[(5-quinoloyloxy)methyl]-1-piperazineethanol trihydrochloride; 1-Piperazineethanol, 4-[(1aR,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-α-[(5-quinolinyloxy)methyl]-, (αR)-, hydrochloride (1:3); (2R)-1-{4-[(1aR,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl]-1-piperazinyl}-3-(5-quinolinyloxy)-2-propanol trihydrochloride; LY335979; Zosuquidar 3HCl; Zosuquidar (trihydrochloride); LY 335979; LY-335979; RS-33295-198; (αR)-4-[(1aα,6α,10bα)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-α-[(5-quinolinyloxy)methyl]-1-piperazineethanol trihydrochloride
- 用途
- 作为P-glycoprotein介导的多药耐抗性调节剂，用于生命科学领域；在无细胞试验中Ki为60 nM，可竞争性抑制表达P-gp的白血病细胞系（如K562/HHT40等），恢复药物敏感性，增强蒽环类药物和gemtuzumab ozogamicin的毒性；在体内研究中，口服25 mg/kg可使紫杉醇给药后1小时和24小时脑浓度分别增加约2.5倍和5倍，增强nelfinavir的脑摄取（剂量依赖性）。
